Search Results - "Adams, C. Brooke"

Utilization of cefepime therapeutic drug monitoring in febrile neutropenia patients with hematologic malignancies by Lodl, Emma F, Alshaer, Mohammad H, Adams, C. Brooke, Richards, Ashley, Peloquin, Charles, Venugopalan, Veena

“…Introduction Cefepime is a fourth-generation cephalosporin and is a workhorse for the empiric treatment of febrile neutropenia (FN). Beta-lactam therapeutic…”
Get full text

Evaluating the incidence of engraftment syndrome with different melphalan formulations in adult multiple myeloma and immunoglobulin light chain amyloidosis patients undergoing autologous hematopoietic cell transplantation by Kowalski, Kaitlyn E, Wheeler, Sarah E, Adams, C Brooke, Voils, Stacy A, Richards, Ashley I

“…Background Engraftment syndrome (ES) is a common complication of autologous hematopoietic cell transplantation (HCT). The difference in incidence of ES between…”
Get full text

Building a precision oncology workforce by multidisciplinary and case-based learning by Chamala, Srikar, Maness, Heather T D, Brown, Lisa, Adams, C Brooke, Lamba, Jatinder K, Cogle, Christopher R

“…Participants in two recent National Academy of Medicine workshops identified a need for more multi-disciplinary professionals on teams to assist oncology…”
Get full text

Use of Patient and Disease Characteristics as Predictive Indicators of Rituximab Infusion-Related Reactions in Adult Malignant Hematology Patients at an Academic Medical Center by Kowalski, Kaitlyn E., Adams, C. Brooke, Voils, Stacy A., Wheeler, Sarah E.

“…Identification of predictive indicators for rituximab infusion-related reactions (R-IRRs) may allow clinicians to modify treatment plans for patients at high…”
Get full text

Low rate of cetuximab hypersensitivity reactions in Northeast Tennessee: An Appalachian effect? by Adams, C Brooke, Street, D Sierra, Crass, Melanie, Bossaer, John B

“…Purpose Cetuximab is a monoclonal antibody with a known risk of hypersensitivity reactions. Early studies showed hypersensitivity reaction rates of 3%, but…”
Get full text